Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Use of Vagus Nerve Stimulation (VNS) in the Management of Patients with Difficult-to-Treat Major Depressive Disorder (MDD): An Expert Consensus Statement.

Neuropsychiatric disease and treatment·2026

Same author

Brief Psychotic Episodes and Depressed Mood in a Patient With Borderline Personality Disorder and Antiphospholipid Syndrome.

Cureus·2024

Same author

Borderline Personality Disorder With Atypical Traits in a 30-Year-Old Female: A Case Report.

Cureus·2024

Same author

Psychological Testing in a Complex Case: Psychosis in Co-occurring PTSD, Gender Dysphoria, and Bipolar Disorder.

Cureus·2024

Same author

Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences.

International clinical psychopharmacology·2023

Same author

Psychiatric Disorder in a Patient With Beckwith-Wiedemann Syndrome: A Case Report.

Cureus·2023

Search research articles

Related Experiment Video

Updated: May 27, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Obesity and psychotropics.

Nikhil Nihalani¹, Thomas L Schwartz, Umar A Siddiqui

¹SUNY Upstate Medical University, NY, USA.

CNS Neuroscience & Therapeutics

|November 11, 2011

Summary

Weight gain is increasing alongside mental health diagnoses. Many psychotropic medications contribute to obesity, increasing risks for metabolic disorders like diabetes and hypertension.

Area of Science:

Psychiatry and Endocrinology
Metabolic Health Research

Background:

Rising rates of obesity and mental health disorders in the US.
Common overlap between psychotropic medication use and weight gain.
Association of weight gain with metabolic disorders like diabetes, hypercholesterolemia, and hypertension.

Purpose of the Study:

To review the epidemiology, etiology, and treatment of psychotropic-induced obesity.
To synthesize current knowledge on medication-associated weight gain.
To inform clinical practice regarding metabolic side effects of psychiatric drugs.

Main Methods:

Literature review of epidemiological data.
Analysis of etiological factors contributing to weight gain.
Summary of current treatment strategies for obesity in psychiatric patients.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Related Experiment Videos

Last Updated: May 27, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Main Results:

Psychotropic medications are frequently linked to significant weight gain.
Weight gain induced by these medications elevates the risk of metabolic syndrome.
Evidence-based treatment options for managing this side effect are available.

Conclusions:

Psychotropic-induced obesity is a significant clinical concern requiring proactive management.
Understanding the link between psychiatric drugs and weight gain is crucial for patient health.
Integrated approaches to mental health and metabolic care are recommended.